ArticleCNS neuroscience & therapeutics2026
Temporal Mapping of CSVD-Related White Matter Lesions and Concurrent Neurovascular Dysfunction in Spontaneously Hypertensive Rats.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo define the critical onset window and mechanisms of white matter lesions (WMLs) in cerebral small vessel disease based on spontaneously hypertensive rat (SHR).
methodsSHRs and age-matched Wistar-Kyoto (WKY) rats were assessed from 20 to 36 weeks of age. Systolic blood pressure, beam-walking performance, and magnetic resonance imaging (MRI)-based white matter changes were evaluated at 4-week intervals. At each time point, randomly selected animals were euthanized for histological analysis. Gait performance and novel object recognition were further assessed at 36 weeks of age. Additional histopathological, neurovascular, neuroinflammatory, transcriptomic, proteomic, and biochemical analyses were performed at the identified critical time point.
resultsSHRs developed sustained hypertension and early small-vessel morphological alterations from 20 weeks, followed by corpus callosum demyelination at 28 weeks and motor, gait, and non-spatial memory deficits by 36 weeks. MRI identified 28 weeks as the onset of detectable white matter microstructural impairment, marked by reduced fractional anisotropy, axial diffusivity, and increased radial diffusivity. At this stage, histological and molecular analyses confirmed myelin disruption, altered mature oligodendrocyte (OL)- and oligodendrocyte precursor cell (OPC)-associated marker profiles, microvascular rarefaction, blood-brain barrier disruption, and inflammation in SHRs. Transcriptomic analysis highlighted cAMP pathway dysregulation, whereas proteomic analysis identified Pde10a as a significantly upregulated candidate protein. Suppression of downstream cAMP/PKA/CREB signaling was further supported by biochemical validation.
conclusionsWMLs emerge at 28 weeks in SHRs and are accompanied by convergent neurovascular injury and inflammatory activation. Pde10a-associated cAMP signaling may represent a candidate mechanism associated with hypertension-related WML development in CSVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.